Complement Dependent Inflammation and Murine Heart Transplant Rejection
补体依赖性炎症和小鼠心脏移植排斥
基本信息
- 批准号:9915875
- 负责人:
- 金额:$ 19.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-03 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AllograftingAntibodiesAntigen PresentationAntigensAreaAwardB-Cell ActivationBiologyCellular ImmunityClinicalCommunicationComplementComplement ActivationCross PresentationDataEnvironmentEragrostisExperimental ModelsFacultyFosteringFunctional disorderGeneticGraft RejectionGrantHeart TransplantationHeart failureHumanHuman ResourcesImageImmune responseImmunityImmunobiologyImmunoglobulin Class SwitchingImmunologyImmunosuppressionInflammationIschemiaKidney FailureKnock-outKnowledgeLeadLectin InhibitorLinkMannose Binding LectinManuscriptsMature B-LymphocyteMediatingMediator of activation proteinMentorsModelingMusNephrologyOrganOrgan DonorOutcomePathogenicityPatientsPharmacologyReperfusion InjuryReperfusion TherapyResearchResearch PersonnelResistanceScientistStatistical Data InterpretationT cell responseT-Cell ActivationT-LymphocyteTestingTrainingTraining ActivityTranslatingTransplant RecipientsTransplantationWritingactivation-induced cytidine deaminaseadaptive immunityallograft rejectioncareer developmenteffector T cellexosomegraft failureheart allografthuman diseaseimmunogenicityimprovedinhibitor/antagonistinsightisoimmunitylarge datasetsmedical schoolsmouse modelnew therapeutic targetpost-transplantpre-clinicalskillstransplant model
项目摘要
Project Summary/Abstract
Research Summary: Long-term post-transplant outcomes remain suboptimal, especially for recipients
of deceased donor organs. Building upon previous studies, our preliminary data from a murine heart
transplant model implicate peri-transplant complement-mediated ischemia reperfusion (IR) injury and
inflammation as a central mediator of increased alloimmunity and late graft failure/dysfunction. In this
project we will study the mechanisms and effects of complement activation on IR-associated
inflammation (Aim 1) and the mechanisms linking increased IR-induced complement-dependent
inflammation to late post-transplant allospecific immunity and outcomes (Aim 2). These aims will test
our central hypothesis that IR-injury induced inflammation is dependent upon recipient mannose
binding lectin-dependent complement activation, that inflammation induces greater recipient APC
activation/donor antigen acquisition, and that these primed APCs then foster a stronger adaptive anti-
donor T cell response leading to graft rejection. The specific findings have the potential to identify
novel therapeutic targets that can be translated to human trials to improve transplant outcomes.
Environment: Both the Icahn School of Medicine at Mount Sinai and Division of Nephrology are firmly
committed to junior faculty career development. Dr. Peter Heeger (mentor) is an established expert in
the field of complement immunology and transplant research with a strong record of developing junior
faculty into independent researchers. Candidate Training: The primary objective of this application is
to support Dr. Nicholas Chun's career development into an independent researcher scientist in the field
of complement immunobiology and human disease. Dr. Chun's proposed training activities are in four
broad non-mutually exclusive areas: 1) Enhancement of fundamental knowledge (e.g. immunology,
complement, and exosome biology); 2) Scientific Communication (e.g. manuscript/grant writing,
presentation skills); 3) Practical skills (e.g. statistical analysis, large data set analysis, advanced
imaging); 4) Managerial skills (e.g. lab finances, personnel administration). The general approaches
and skills outlined during this award will form the basis for future research.
!
项目总结/摘要
研究总结:移植后长期结局仍不理想,尤其是对受者而言
死者捐赠器官基于先前的研究,我们从小鼠心脏获得的初步数据
移植模型涉及移植周围补体介导缺血再灌注(IR)损伤,
炎症作为增加的同种异体免疫和晚期移植物衰竭/功能障碍的中心介质。在这
本项目将研究补体激活对IR相关的免疫反应的机制和作用。
炎症(目的1)和IR诱导的补体依赖性增加的机制
炎症对移植后晚期同种异体免疫和结果的影响(目的2)。这些目标将检验
我们的中心假设是IR损伤诱导的炎症依赖于受体甘露糖
结合凝集素依赖性补体激活,炎症诱导更大的受体APC
激活/供体抗原获取,然后这些引发的APC培养更强的适应性抗-
供体T细胞反应导致移植物排斥。具体的调查结果有可能确定
新的治疗靶点可以转化为人体试验,以改善移植结果。
环境:西奈山伊坎医学院和肾脏科都坚定地
致力于初级教师的职业发展。Peter Heeger博士(导师)是一位公认的专家,
在补体免疫学和移植研究领域,
成为独立的研究人员。候选人培训:此应用程序的主要目标是
支持Nicholas Chun博士的职业发展成为该领域的独立研究员科学家
补体免疫生物学和人类疾病的关系秦博士建议的培训活动分为四个部分
广泛的非相互排斥的领域:1)加强基础知识(如免疫学,
补体和外泌体生物学); 2)科学交流(例如手稿/资助写作,
3)实践技能(如统计分析、大型数据集分析、高级
4)管理技能(如实验室财务、人事管理)。一般方法
和技能概述在这个奖项将形成未来的研究基础。
!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicholas Chun其他文献
Nicholas Chun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicholas Chun', 18)}}的其他基金
Complement-Mediated Exosome Function in Transplantation
移植中补体介导的外泌体功能
- 批准号:
10709593 - 财政年份:2022
- 资助金额:
$ 19.03万 - 项目类别:
Complement-Mediated Exosome Function in Transplantation
移植中补体介导的外泌体功能
- 批准号:
10563092 - 财政年份:2022
- 资助金额:
$ 19.03万 - 项目类别:
Complement Dependent Inflammation and Murine Heart Transplant Rejection
补体依赖性炎症和小鼠心脏移植排斥
- 批准号:
10394223 - 财政年份:2018
- 资助金额:
$ 19.03万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 19.03万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 19.03万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 19.03万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 19.03万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:














{{item.name}}会员




